Adverum Biotechnologies' Promising AMD Treatment Advances

TipRanks16:58 ET

Adverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal Study

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD).The 26-week interim analysis was

Benzinga14:54 ET

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for

Benzinga13:28 ET

Adverum Biotechnologies Shares Rise As Eye Disease Treatment Study Advances

By Michael Susin Adverum Biotechnologies shares were higher early Wednesday after the company said that its therapy for wet age-related macular degeneration was selected for a late-stage study.

WSJJul 17 06:36 ET

Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug

Adverum Biotechnologies (ADVM) said Wednesday that a 26-week interim analysis of its mid-stage trial of its novel gene therapy candidate, Ixo-vec, in patients with wet age-related macular

MT NewswiresJul 17 06:20 ET

Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave.Bloom Energy said it entered into a

BenzingaJul 17 06:03 ET